13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001727492
Total reported value
$2.1B
$2.1B
12 檔
14.5%
The Q1 2024 SEC filing reveals that Caligan Partners LP held a total portfolio value of $2.1B, covering 12 public equity positions.
During Q1 2024, Caligan Partners LP's portfolio maintained high stability with no major positional turnover, reflecting a continuous long-term holding approach.
In terms of portfolio concentration, the top 5 core holdings (including LQDA, ALIMERA SCIENCES INC, ANIK) accounted for 14.5% of total reported equity market value during Q1 2024.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | LQDA | Liquidia CORP | Stock-Other | 40.40% | +10.06% | — | |
| 2 | ✓ | Alimera Sciences Inc | Stock-Other | 17.36% | — | — | |
| 3 | ANIK | Anika Therapeutics Inc | Stock-Other | 9.64% | -0.39% | +32.80% | |
| 4 | EOLS | Evolus Inc | Stock-Other | 6.99% | — | +43.33% | |
| 5 | EXEL | Exelixis Inc | Stock-Healthcare | 6.90% | -0.45% | +20.86% | |
| 6 | VRNA | Verona Pharma PLC - Adr | Stock-Other | 5.51% | — | +608.19% | |
| 7 | ENTA | Enanta Pharmaceuticals Inc | Stock-Other | 3.96% | — | — | |
| 8 | AGIO | Agios Pharmaceuticals Inc | Stock-Other | 3.75% | -0.04% | +9.70% | |
| 9 | YMABUSD | Y-mabs Therapeutics Inc | Stock-Other | 2.52% | — | -43.98% | |
| 10 | OTLK | Outlook Therapeutics Inc | Stock-Other | 1.58% | — | — | |
| 11 | BCRX | Biocryst Pharmaceuticals Inc | Stock-Other | 1.02% | — | — | |
| 12 | NBP | Novabridge Biosciences | Stock-Other | 0.37% | — | — |
According to official SEC Form 13F filings, Caligan Partners LP reported a total U.S. public equity portfolio value of $2.1B across 12 disclosed positions in Q1 2024.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
During Q1 2024, Caligan Partners LP's top holdings by market value included LQDA (40.4%)、ALIMERA SCIENCES INC (17.4%)、ANIK (9.6%). The largest single position, LQDA, represented 40.4% of total portfolio value.
In Q1 2024, Caligan Partners LP made 0 total portfolio adjustments, initiating 0 new buys, adding to 0 positions, trimming 0 holdings, and fully liquidating 0 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.